Phase 2
Completed N=594
Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Source: ClinicalTrials.gov NCT00247611 ↗
Enrolled (actual)
594
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcomePrimary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
Summary
This study will develop and evaluate the efficacy of an individualized, interactive, computer software program delivered in conjunction with clinical care in increasing and supporting antiretroviral therapy adherence in HIV-infected individuals.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken |
72.89; 75.46; 74.86; 77.33; 80.36; 82.48 | 0.12 |
| PRIMARY Visual Analog Scale Measure of Adherence to ART |
42.61; 46.15; 45.71; 45.33; 43.27; 47.81 | 0.12 |
| SECONDARY Viral Load Count |
73.9; 70.3; 70.3; 77.0; 73.4; 75.0 | >0.50 |
Eligibility Criteria
Inclusion Criteria
- HIV-infected
- English-speaking
- Currently receiving treatment at one of the participating sites
- Currently receiving antiretroviral therapy
Exclusion Criteria
- Marked cognitive impairment
Data sourced from ClinicalTrials.gov (NCT00247611). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.